Method of Screening Compounds Inhibiting Pancreatic Cancer RNF43 Mutation

The USPTO granted Patent US12600785B2 to Antlera Therapeutics Inc. for a method of screening compounds that inhibit proliferation of pancreatic cancer cells having a loss-of-function mutation in the RNF43 gene. The patent discloses novel FZD5-binding agents and methods for treating diseases associated with aberrant Frizzled protein expression. The patent was filed on February 15, 2021, and contains 5 claims.

For pharmaceutical companies and biotechnology firms developing targeted cancer therapies, this patent establishes proprietary rights over a specific method of identifying compounds that target RNF43-mutated pancreatic cancer cells. Researchers should conduct freedom-to-operate analyses before initiating related compound screening programs. The patent may also block or require licensing for competing therapeutic development in the FZD5/RNF43 pathway space for pancreatic cancer treatment.